Bradley Canino
Stock Analyst at Stifel
(2.02)
# 3,065
Out of 4,981 analysts
88
Total ratings
34.18%
Success rate
-2.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Reinstates: Buy | $44 | $15.55 | +182.96% | 7 | Sep 10, 2025 | |
| JANX Janux Therapeutics | Reinstates: Buy | $45 | $24.05 | +87.11% | 3 | Sep 10, 2025 | |
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $3.25 | +361.54% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $1.06 | +41.51% | 8 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $23 → $19 | $6.53 | +190.96% | 2 | Feb 28, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $3.99 | +476.44% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $7.74 | +558.91% | 6 | Feb 12, 2025 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $8.19 | +131.99% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $54.91 | -23.51% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $18.94 | +111.19% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $80.54 | +67.62% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $10.78 | +85.53% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.82 | +449.45% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $1.49 | +571.14% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $99 | $69.53 | +42.38% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $2.66 | +426.32% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $47.00 | +17.02% | 4 | Feb 23, 2024 |
Syndax Pharmaceuticals
Sep 10, 2025
Reinstates: Buy
Price Target: $44
Current: $15.55
Upside: +182.96%
Janux Therapeutics
Sep 10, 2025
Reinstates: Buy
Price Target: $45
Current: $24.05
Upside: +87.11%
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $3.25
Upside: +361.54%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $1.06
Upside: +41.51%
Cullinan Therapeutics
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $19
Current: $6.53
Upside: +190.96%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $3.99
Upside: +476.44%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $7.74
Upside: +558.91%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $8.19
Upside: +131.99%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $54.91
Upside: -23.51%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $18.94
Upside: +111.19%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $80.54
Upside: +67.62%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $10.78
Upside: +85.53%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $1.82
Upside: +449.45%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $1.49
Upside: +571.14%
Jun 17, 2024
Maintains: Buy
Price Target: $90 → $99
Current: $69.53
Upside: +42.38%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $2.66
Upside: +426.32%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $47.00
Upside: +17.02%